

**Food and Drug Administration**  
**Cardiovascular and Renal Drugs Advisory Committee**

**February 24, 2005**

**Briefing Information**

**AstraZeneca LP**

*Disclaimer*

*The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.*

[ATACAND® \(candesartan cilexetil\) Tablets Briefing Document NDA 20-838/S-022, S-024, S-025](#)

[ATACAND® \(candesartan cilexetil\) Tablets \(Addendum\) to Briefing Document NDA 20-838/S-022, S-024, S-025](#)

**FDA**

*Disclaimer*

*Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552). These redacted portions will appear as white space on the screen or on the printed page.*

*In addition, for this particular document, a technical problem with the software has resulted in a misnumbering of the pages. In Tab 7 of the FDA briefing document, page 66 is followed immediately by page 74. This is strictly a problem with the page numbering, and no text has been deleted from the document.*

FDA Backgrounder